MOREPENLAB Latest Share Price (MOREPENLAB)
TODAY IN ONE LINE
With a market cap of ₹6,778.19 Cr., it trades at a P/E of 49.06. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
MOREPENLAB flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.16x
- ●FII AccumulationFII holding increased by 1.97% QoQ
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 18.9% YoY
- ●Poor Capital ReturnsLow ROE of 5.3%
- ●Rising Receivables vs SalesReceivables grew 11.4% outpacing sales growth of 7.2%
Latest MOREPENLAB News
What changed recently?
Recent events, corporate actions, and announcements.
MOREPENLAB valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for MOREPENLAB, framed against the sector median so the premium or discount is obvious at a glance.
MOREPENLAB trades at a P/E of 49.06× and P/B of 5.52×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
MOREPENLAB technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for MOREPENLAB — derived from the latest tape, not yesterday's close.
MOREPENLAB last traded at ₹127.83 with an intraday range of ₹123.82–₹133.7 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹127.83| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 152.84 | +25.01 | +19.57% |
| R3 | 142.96 | +15.13 | +11.84% |
| R2 | 138.33 | +10.50 | +8.21% |
| R1 | 133.08 | +5.25 | +4.11% |
| PIVOT | 128.45 | 0.62 | 0.49% |
| CURRENT | 127.83 | — | — |
| S1 | 123.20 | -4.63 | -3.62% |
| S2 | 118.57 | -9.26 | -7.24% |
| S3 | 113.32 | -14.51 | -11.35% |
| S4 | 103.44 | -24.39 | -19.08% |
MOREPENLAB is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹–₹
Trading Inside opening range
MOREPENLAB financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for MOREPENLAB — consolidated or standalone — with margins, YoY growth and key ratios inline.
MOREPENLAB reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹6,778.19 Cr. and reported EPS of ₹1.03.
| Metric | Mar 2026 | May 2026 |
|---|---|---|
| Revenue from Operations | 1,806 | 1,806 ▲ 0.0% |
| Sales Growth YoY %Derived | -0.32% | -0.32% |
| Other Income | 21 | 21 ▲ 0.0% |
| Total Income | 1,827 | 1,827 ▲ 0.0% |
| 1,123 | 1,123 ▲ 0.0% | |
| Gross ProfitDerived | 682 | 682 ▲ 0.0% |
| Gross Margin %Derived | 37.78% | 37.78% |
| 557 | 557 ▲ 0.0% | |
| EBITDA (Operating Profit)Derived | 126 | 126 ▲ 0.0% |
| OPM %Derived | 6.96% | 6.96% |
| 79 | 79 ▲ 0.0% | |
| Profit Before Tax (PBT) | 120 | 120 ▲ 0.0% |
| 24 | 24 ▲ 0.0% | |
| Effective Tax %Derived | 20.24% | 20.24% |
| Total Profit for Period | 95 | 95 ▲ 0.0% |
| Net Profit (Owner's PAT)Derived | 95 | 95 ▲ 0.0% |
| Net Profit Margin %Derived | 5.25% | 5.25% |
| PAT Growth YoY %Derived | -19.61% | -19.61% |
| Earnings Per Share (EPS ₹) | 1.73 | 1.73 ▲ 0.0% |
| Diluted Shares Outstanding (Cr) | 55 | 55 ▲ 0.0% |
| Share of Profit from Associates/JVs | -1 | -1 ▲ 0.0% |
| Other Comprehensive Income (Net of Tax) | 6 | 6 ▲ 0.0% |
| Total Expenses (incl. D&A & Interest) | 1,707 | 1,707 ▲ 0.0% |
| Material Cost % of RevenueDerived | 57.77% | 57.77% |
| Employee Cost % of RevenueDerived | 12.89% | 12.89% |
| Other Cost % of RevenueDerived | 17.94% | 17.94% |
| Interest Coverage (x)Derived | 5.43x | 5.43x |
| Period | Mar 2018 | May 2018 | Mar 2019 | May 2019 | Mar 2020 | Jun 2020 | Mar 2021 | May 2021 | Mar 2022 | May 2022 | Mar 2023 | May 2023 | Mar 2024 | May 2024 | Mar 2025 | May 2025 | Mar 2026 | May 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 607 | 607 ▲ 0.0% | 769 ▲ 26.7% | 769 ▲ 0.0% | 853 ▲ 11.0% | 853 ▲ 0.0% | 1,188 ▲ 39.3% | 1,188 ▲ 0.0% | 1,547 ▲ 30.2% | 1,547 ▲ 0.0% | 1,418 ▼ 8.4% | 1,418 ▲ 0.0% | 1,690 ▲ 19.3% | 1,690 ▲ 0.0% | 1,812 ▲ 7.2% | 1,812 ▲ 0.0% | 1,806 ▼ 0.3% | 1,806 ▲ 0.0% | |
| Sales Growth YoY %Derived | — | — | 26.72% | 26.72% | 11.00% | — | 39.27% | — | 30.20% | 30.20% | -8.36% | -8.36% | 19.25% | 19.25% | 7.17% | 7.17% | -0.32% | -0.32% | |
| Other Income | 4 | 4 ▲ 0.0% | 4 ▼ 1.4% | 4 ▲ 0.0% | 9 ▲ 158.3% | 9 ▲ 0.0% | 12 ▲ 27.3% | 12 ▲ 0.0% | 10 ▼ 14.6% | 10 ▲ 0.0% | 6 ▼ 40.5% | 6 ▲ 0.0% | 14 ▲ 127.8% | 14 ▲ 0.0% | 18 ▲ 31.4% | 18 ▲ 0.0% | 21 ▲ 16.1% | 21 ▲ 0.0% | |
| Total Income | 610 | 610 ▲ 0.0% | 772 ▲ 26.5% | 772 ▲ 0.0% | 863 ▲ 11.7% | 863 ▲ 0.0% | 1,200 ▲ 39.1% | 1,200 ▲ 0.0% | 1,557 ▲ 29.7% | 1,557 ▲ 0.0% | 1,424 ▼ 8.6% | 1,424 ▲ 0.0% | 1,704 ▲ 19.7% | 1,704 ▲ 0.0% | 1,830 ▲ 7.4% | 1,830 ▲ 0.0% | 1,827 ▼ 0.2% | 1,827 ▲ 0.0% | |
369 | 369 ▲ 0.0% | 496 ▲ 34.7% | 496 ▲ 0.0% | 557 ▲ 12.3% | 557 ▲ 0.0% | 781 ▲ 40.0% | 781 ▲ 0.0% | 1,049 ▲ 34.4% | 1,049 ▲ 0.0% | 956 ▼ 8.9% | 956 ▲ 0.0% | 1,062 ▲ 11.2% | 1,062 ▲ 0.0% | 1,159 ▲ 9.1% | 1,159 ▲ 0.0% | 1,123 ▼ 3.1% | 1,123 ▲ 0.0% | ||
| Gross ProfitDerived | 238 | 238 ▲ 0.0% | 272 ▲ 14.3% | 272 ▲ 0.0% | 296 ▲ 8.7% | 296 ▲ 0.0% | 408 ▲ 37.8% | 408 ▲ 0.0% | 498 ▲ 22.1% | 498 ▲ 0.0% | 462 ▼ 7.2% | 462 ▲ 0.0% | 628 ▲ 36.0% | 628 ▲ 0.0% | 652 ▲ 3.9% | 652 ▲ 0.0% | 682 ▲ 4.6% | 682 ▲ 0.0% | |
| Gross Margin %Derived | 39.23% | 39.23% | 35.40% | 35.40% | 34.66% | 34.66% | 34.30% | 34.30% | 32.16% | 32.16% | 32.58% | 32.58% | 37.15% | 37.15% | 36.01% | 36.01% | 37.78% | 37.78% | |
173 | 173 ▲ 0.0% | 205 ▲ 18.1% | 205 ▲ 0.0% | 227 ▲ 11.1% | 227 ▲ 0.0% | 289 ▲ 27.2% | 289 ▲ 0.0% | 361 ▲ 24.9% | 361 ▲ 0.0% | 382 ▲ 5.9% | 382 ▲ 0.0% | 469 ▲ 22.8% | 469 ▲ 0.0% | 478 ▲ 1.9% | 478 ▲ 0.0% | 557 ▲ 16.4% | 557 ▲ 0.0% | ||
| EBITDA (Operating Profit)Derived | 65 | 65 ▲ 0.0% | 68 ▲ 4.3% | 68 ▲ 0.0% | 69 ▲ 1.5% | 69 ▲ 0.0% | 119 ▲ 73.0% | 119 ▲ 0.0% | 137 ▲ 15.3% | 137 ▲ 0.0% | 80 ▼ 41.8% | 80 ▲ 0.0% | 159 ▲ 99.4% | 159 ▲ 0.0% | 174 ▲ 9.7% | 174 ▲ 0.0% | 126 ▼ 27.8% | 126 ▲ 0.0% | |
| OPM %Derived | 10.67% | 10.67% | 8.79% | 8.79% | 8.03% | 8.03% | 9.98% | 9.98% | 8.84% | 8.84% | 5.61% | 5.61% | 9.38% | 9.38% | 9.61% | 9.61% | 6.96% | 6.96% | |
39 | 39 ▲ 0.0% | 42 ▲ 8.6% | 42 ▲ 0.0% | 39 ▼ 7.4% | 39 ▲ 0.0% | 32 ▼ 17.5% | 32 ▲ 0.0% | 20 ▼ 36.8% | 20 ▲ 0.0% | 30 ▲ 47.5% | 30 ▲ 0.0% | 37 ▲ 24.3% | 37 ▲ 0.0% | 37 ▲ 0.4% | 37 ▲ 0.0% | 79 ▲ 110.8% | 79 ▲ 0.0% | ||
| Profit Before Tax (PBT) | 30 | 30 ▲ 0.0% | 29 ▼ 2.0% | 29 ▲ 0.0% | 39 ▲ 34.0% | 39 ▲ 0.0% | 99 ▲ 151.9% | 99 ▲ 0.0% | 127 ▲ 28.6% | 127 ▲ 0.0% | 56 ▼ 56.0% | 56 ▲ 0.0% | 135 ▲ 142.9% | 135 ▲ 0.0% | 155 ▲ 14.5% | 155 ▲ 0.0% | 120 ▼ 22.7% | 120 ▲ 0.0% | |
— | — | 0 | 0 ▲ 0.0% | 6 ▲ 1544.0% | 6 ▲ 0.0% | 1 ▼ 74.3% | 1 ▲ 0.0% | 25 ▲ 1660.2% | 25 ▲ 0.0% | 17 ▼ 31.7% | 17 ▲ 0.0% | 39 ▲ 127.1% | 39 ▲ 0.0% | 37 ▼ 4.4% | 37 ▲ 0.0% | 24 ▼ 34.6% | 24 ▲ 0.0% | ||
| Effective Tax %Derived | — | — | 1.15% | 1.15% | 14.14% | 14.14% | 1.44% | 1.44% | 19.75% | 19.75% | 30.63% | 30.63% | 28.65% | 28.65% | 23.91% | 23.91% | 20.24% | 20.24% | |
| Total Profit for Period | 30 | 30 ▲ 0.0% | 29 ▼ 2.5% | 29 ▲ 0.0% | 34 ▲ 16.4% | 34 ▲ 0.0% | 97 ▲ 189.1% | 97 ▲ 0.0% | 102 ▲ 4.7% | 102 ▲ 0.0% | 39 ▼ 62.0% | 39 ▲ 0.0% | 96 ▲ 148.6% | 96 ▲ 0.0% | 118 ▲ 22.7% | 118 ▲ 0.0% | 95 ▼ 19.6% | 95 ▲ 0.0% | |
| Net Profit (Owner's PAT)Derived | 30 | 30 ▲ 0.0% | 29 ▼ 2.5% | 29 ▲ 0.0% | 34 ▲ 16.4% | 34 ▲ 0.0% | 97 ▲ 189.1% | 97 ▲ 0.0% | 102 ▲ 4.7% | 102 ▲ 0.0% | 39 ▼ 62.0% | 39 ▲ 0.0% | 96 ▲ 148.6% | 96 ▲ 0.0% | 118 ▲ 22.7% | 118 ▲ 0.0% | 95 ▼ 19.6% | 95 ▲ 0.0% | |
| Net Profit Margin %Derived | 4.88% | 4.88% | 3.75% | 3.75% | 3.94% | 3.94% | 8.17% | 8.17% | 6.57% | 6.57% | 2.73% | 2.73% | 5.69% | 5.69% | 6.51% | 6.51% | 5.25% | 5.25% | |
| PAT Growth YoY %Derived | — | — | -2.51% | -2.51% | 16.40% | — | 189.13% | — | 4.73% | 4.73% | -61.96% | -61.96% | 148.63% | 148.63% | 22.73% | 22.73% | -19.61% | -19.61% | |
| Earnings Per Share (EPS ₹) | 0.66 | 0.66 ▲ 0.0% | 0.64 ▼ 3.0% | 0.64 ▲ 0.0% | 0.75 ▲ 17.2% | 0.75 ▲ 0.0% | 2.16 ▲ 188.0% | 2.16 ▲ 0.0% | 2.13 ▼ 1.4% | 2.13 ▲ 0.0% | 0.76 ▼ 64.3% | 0.76 ▲ 0.0% | 1.88 ▲ 147.4% | 1.88 ▲ 0.0% | 2.15 ▲ 14.4% | 2.15 ▲ 0.0% | 1.73 ▼ 19.5% | 1.73 ▲ 0.0% | |
| Diluted Shares Outstanding (Cr) | 45 | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 45 ▲ 0.0% | 48 ▲ 6.2% | 48 ▲ 0.0% | 51 ▲ 7.0% | 51 ▲ 0.0% | 51 ▲ 0.0% | 51 ▲ 0.0% | 55 ▲ 7.2% | 55 ▲ 0.0% | 55 ▲ 0.0% | 55 ▲ 0.0% | |
| Share of Profit from Associates/JVs | -0 | -0 ▲ 0.0% | 0 ▲ 105.0% | 0 ▲ 0.0% | 0 ▼ 96.6% | 0 ▲ 0.0% | -0 ▼ 1466.7% | -0 ▲ 0.0% | 0 ▲ 134.1% | 0 ▲ 0.0% | -0 ▼ 121.4% | -0 ▲ 0.0% | -0 ▼ 153366.7% | -0 ▲ 0.0% | 0 ▲ 101.1% | 0 ▲ 0.0% | -1 ▼ 15494.0% | -1 ▲ 0.0% | |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▲ 0.0% | -2 ▼ 2014.4% | -2 ▲ 0.0% | -3 ▼ 53.8% | -3 ▲ 0.0% | -0 ▲ 94.4% | -0 ▲ 0.0% | -0 ▼ 152.0% | -0 ▲ 0.0% | -1 ▼ 299.0% | -1 ▲ 0.0% | -2 ▼ 24.4% | -2 ▲ 0.0% | 0 ▲ 113.8% | 0 ▲ 0.0% | 6 ▲ 2339.5% | 6 ▲ 0.0% | |
| Total Expenses (incl. D&A & Interest) | 580 | 580 ▲ 0.0% | 743 ▲ 28.0% | 743 ▲ 0.0% | 823 ▲ 10.8% | 823 ▲ 0.0% | 1,102 ▲ 33.8% | 1,102 ▲ 0.0% | 1,430 ▲ 29.8% | 1,430 ▲ 0.0% | 1,368 ▼ 4.4% | 1,368 ▲ 0.0% | 1,569 ▲ 14.7% | 1,569 ▲ 0.0% | 1,675 ▲ 6.7% | 1,675 ▲ 0.0% | 1,707 ▲ 1.9% | 1,707 ▲ 0.0% | |
| Material Cost % of RevenueDerived | 36.36% | 36.36% | 44.64% | 44.64% | 48.44% | 48.44% | 52.01% | 52.01% | 51.53% | 51.53% | 55.12% | 55.12% | 52.25% | 52.25% | 55.16% | 55.16% | 57.77% | 57.77% | |
| Employee Cost % of RevenueDerived | 12.62% | 12.62% | 12.41% | 12.41% | 12.88% | 12.88% | 11.41% | 11.41% | 10.62% | 10.62% | 10.91% | 10.91% | 10.73% | 10.73% | 11.53% | 11.53% | 12.89% | 12.89% | |
| Other Cost % of RevenueDerived | 15.94% | 15.94% | 14.20% | 14.20% | 13.74% | 13.74% | 12.91% | 12.91% | 12.71% | 12.71% | 16.05% | 16.05% | 17.03% | 17.03% | 14.86% | 14.86% | 17.94% | 17.94% | |
| Interest Coverage (x)Derived | 6.98x | 6.98x | 13.09x | 13.09x | 15.93x | 15.93x | 49.34x | 49.34x | -14.80x | -14.80x | 26.05x | 26.05x | 33.73x | 33.73x | 17.39x | 17.39x | 5.43x | 5.43x |
MOREPENLAB segment analysis : revenue and profit mix.
Disclosed business segments at MOREPENLAB with their share of revenue and profit, switchable between consolidated and standalone reporting.
MOREPENLAB discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for MOREPENLAB.
Our AI distills the core fundamental drivers supporting MOREPENLAB, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Valuation risk. a P/E above 64 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
MOREPENLAB peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — MOREPENLAB is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
MOREPENLAB chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for MOREPENLAB — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
MOREPENLAB delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for MOREPENLAB over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in MOREPENLAB stood at 37.4% of traded volume, against a 20-day average of 30.3%.
MOREPENLAB announcements: results, concalls, ratings, M&A.
Filings MOREPENLAB sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
MOREPENLAB files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 90 documents below.
Trading Window
Morepen Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading)…
Press Release
Morepen Laboratories Limited has informed the Exchange regarding a press release dated September 28, 2026, titled "Morepen strengthens integrated…
Shareholders meeting
Please find attached the Voting Results and the Scrutinizer Report of 41st Annual General Meeting
Shareholders meeting
Morepen Laboratories Limited has informed the Exchange regarding Proceedings of 41st Annual General Meeting held on September 26, 2026
General Updates
Morepen Laboratories Limited has informed the Exchange about ESG Rating.
Investor decks & rating reports.
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
Investor Presentation
MOREPENLAB dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue MOREPENLAB has declared, sequenced by announce and record date.
MOREPENLAB corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About MOREPENLAB: business, sector, key facts.
What MOREPENLAB does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
MOREPENLAB operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: MOREPENLAB, BSE: 500288.
Morepen Laboratories Limited is a multinational company headquartered in Gurugram, India, established in 1984. Their core business revolves around the development, manufacturing, marketing, and sale of a diverse range of healthcare products across several key sectors. This includes a significant presence in the Active Pharmaceutical Ingredients (API) market, providing crucial components for various medications.
A substantial portion of Morepen's business focuses on the production and distribution of APIs. These APIs are used in the creation of pharmaceuticals targeting a wide spectrum of conditions, including allergies (anti-histaminic, anti-asthmatic), cardiovascular issues (anti-lipemic, anti-hypertensive, anti-coagulant), diabetes (anti-diabetic), ulcers (anti-ulcerative), and mental health (anti-depressant). This underscores their significant role in the pharmaceutical supply chain.
Beyond APIs, Morepen Laboratories also manufactures and sells a broad range of home healthcare products. This segment encompasses a considerable selection of diagnostic tools and equipment, such as blood glucose monitors and test strips, blood pressure monitors (sphygmomanometers), digital thermometers, nebulizers, pulse oximeters, and even air purifiers. This comprehensive array of products caters to both professional and personal healthcare needs.
Furthermore, Morepen offers a diverse portfolio of Over-The-Counter (OTC) and healthcare products marketed under the prominent "Dr. Morepen" brand. This includes a wide array of medications and remedies designed to address common ailments like fever, pain, constipation, and acidity. The brand also extends to products focused on specific health areas, encompassing formulations for nutrition and probiotics, gastroenterology, antibiotics, gynecology, allergy treatment, central nervous system disorders, cardiology, diabetology, and nutraceuticals. This demonstrates a strategic approach to capturing a broad market share across various healthcare segments.
In summary, Morepen Laboratories' business model is multifaceted and encompasses a vertically integrated approach from the production of APIs to the development and marketing of finished pharmaceutical products and home healthcare devices. Their geographical reach extends internationally, with a focus on India and the United States, demonstrating a considerable level of market penetration and a robust business strategy.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Other overvalued NSE stocksScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about MOREPENLAB (MOREPENLAB).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of MOREPENLAB (MOREPENLAB)?
The current share price of MOREPENLAB (MOREPENLAB) is ₹127.83. Today, the stock has declined by ₹1.72 (1.33%), trading in a range of ₹123.82 to ₹133.70. The stock opened at ₹129.45 with a trading volume of 1,35,04,386 shares.
02Is MOREPENLAB stock a good investment for long-term?
MOREPENLAB can be considered for long-term investment based on several factors. The company has a market capitalization of ₹6,778.19 Cr., P/E ratio of 49.06, ROE of 5.32%, and ROCE of 5.47%. The dividend yield stands at 0.16%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of MOREPENLAB stock?
The 52-week high price of MOREPENLAB (MOREPENLAB) is ₹150.70, while the 52-week low is ₹33.05. Currently trading at ₹127.83, the stock is 286.78% above its 52-week low and 15.18% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy MOREPENLAB stock at the current price?
Whether to buy MOREPENLAB stock at ₹127.83 depends on multiple factors. The stock is currently trading with a P/E ratio of 49.06 and P/B ratio of 5.52. Today's performance shows a loss of 1.33%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of MOREPENLAB and when is the next dividend?
MOREPENLAB offers a dividend yield of 0.16%, which means for every ₹100 invested at the current price of ₹127.83, you can expect to receive approximately ₹0.16 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of MOREPENLAB?
MOREPENLAB's key financial metrics include: P/E Ratio: 49.06, P/B Ratio: 5.52, ROE: 5.32%, ROCE: 5.47%, Dividend Yield: 0.16%, EPS: ₹1.03, Book Value: ₹22.76, and Debt-to-Equity: 0.16. The company's market cap stands at ₹6,778.19 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is MOREPENLAB stock performing today in the market?
MOREPENLAB stock opened at ₹129.45 and is currently trading at ₹127.83, showing a decline of ₹1.72 (1.33%). The intraday high is ₹133.70 and low is ₹123.82. The trading volume stands at 1,35,04,386 shares, indicating strong market participation today.
08What is the P/E ratio of MOREPENLAB and what does it indicate?
MOREPENLAB has a Price-to-Earnings (P/E) ratio of 49.06, which means investors are willing to pay 49.06 for every ₹1 of earnings. With an EPS of ₹1.03, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about MOREPENLAB (MOREPENLAB) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.